ELI LILLY AND COMPANY Deferred State and Local Income Tax Expense (Benefit)
ELI LILLY AND COMPANY (LLY) reported Deferred State and Local Income Tax Expense (Benefit) of -$31.30 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-19.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit · last filed 2025-02-19
- ELI LILLY AND COMPANY deferred state and local income tax expense (benefit) for fiscal 2024 was -$31.30M.
- ELI LILLY AND COMPANY deferred state and local income tax expense (benefit) for fiscal 2023 was -$6.20M.
- ELI LILLY AND COMPANY deferred state and local income tax expense (benefit) for fiscal 2022 was -$114.60M, a 19200.00% decline from fiscal 2021.
- ELI LILLY AND COMPANY deferred state and local income tax expense (benefit) for fiscal 2021 was $600.00K.
| Period end | Deferred State and Local Income Tax Expense (Benefit) 12 month | Deferred State and Local Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2024-12-31 | -$31.30M 10-K · filed 2025-02-19 | |
| 2023-12-31 | -$6.20M 10-K · filed 2025-02-19 | |
| 2022-12-31 | -$114.60M 10-K · filed 2025-02-19 | |
| 2021-12-31 | $600.00K 10-K · filed 2024-02-21 | |
| 2020-12-31 | -$20.50M 10-K · filed 2023-02-22 | |
| 2019-12-31 | -$54.80M 10-K · filed 2022-02-23 | |
| 2018-12-31 | $3.40M 10-K · filed 2021-02-17 | |
| 2017-12-31 | $200.00K 10-K · filed 2020-02-19 | $400.00K 10-K · filed 2018-02-20 |
| 2016-12-31 | -$4.90M 8-K · filed 2019-10-24 | $5.80M 10-K · filed 2017-02-21 |
| 2015-12-31 | $7.20M 10-K · filed 2018-02-20 | |
| 2014-12-31 | -$100.00K 10-K · filed 2017-02-21 | |
| 2013-12-31 | -$2.90M 10-K · filed 2016-02-19 | |
| 2012-12-31 | $9.10M 10-K · filed 2015-02-19 | |
| 2011-12-31 | $27.00M 10-K · filed 2014-02-19 | |
| 2010-12-31 | -$26.90M 10-K · filed 2013-02-21 | |
| 2009-12-31 | -$400.00K 10-K · filed 2012-02-24 | |
| 2008-12-31 | $6.20M 10-K · filed 2011-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |